Orexin A

Orexin A, also known as hypocretin-1, is a neuropeptide produced by a small population of neurons in the lateral hypothalamus. It is one of two orexin peptides that share a common precursor protein and act as central regulators of arousal, wakefulness, appetite, and reward-related behaviour.

Orexin A is frequently described as the more chemically stable and more extensively studied of the two orexins. It is investigational and is not an approved therapy; discussion here reflects research contexts rather than any established clinical use in peptide form.

Orexin A is notable for activating both orexin receptor subtypes, and its proposed mechanisms centre on this broad receptor engagement:

• Binding and activating both the OX1R and OX2R receptors with roughly comparable affinity
• Signalling through hypothalamic and brainstem circuits that promote and stabilise wakefulness
• Interacting with pathways tied to appetite, energy balance, and reward or motivation

Because orexin neurons project widely across the brain, orexin A is thought to act as an integrator that links arousal state to feeding and motivated behaviour. How these signalling roles translate into measurable outcomes when the peptide is delivered exogenously remains an active research question.

There is no approved orexin A peptide medicine. Interest in the orexin system grew substantially after the discovery that loss of orexin-producing neurons is associated with narcolepsy, a disorder of disrupted wakefulness. This link has made orexin signalling a prominent target in sleep and arousal research.

A specific research interest for orexin A has been intranasal delivery as a route that might reach central targets, explored in experimental settings for alertness and cognition. These remain exploratory investigations rather than validated treatments, and regulatory status, product quality, and evidence strength vary widely.

Orexin A is not among the substances most commonly discussed in anti-doping enforcement. Athletes subject to anti-doping rules should not assume that any investigational or unapproved substance is permitted, because broad catch-all categories can apply to compounds that lack regulatory approval. Anyone in a tested sport should consult current, authoritative anti-doping guidance rather than relying on general summaries.

Because orexin A engages arousal circuitry, effects on sleep, wakefulness, and possibly appetite or cardiovascular tone are conceptually plausible and are areas researchers monitor. Nonspecific effects reported with experimental peptides more broadly include headache, fatigue, or local reactions with a given route of delivery.

Robust, long-term safety data across diverse populations are sparse. As with other experimental neuropeptides, attention to product sourcing, regulatory guidance, and individual risk factors is important, and high-level summaries cannot substitute for rigorous safety evaluation.

Orexin A is a peptide that acts on central receptors, and a key pharmacological challenge discussed in the literature is delivery: reaching brain targets while accounting for stability and how the peptide is distributed and cleared.

This information summarises how researchers frame the peptide conceptually and does not constitute medical advice or any recommendation about use.

Orexin A sits at the centre of a family of compounds that share a target but almost nothing else in terms of evidence or availability:

• Orexin B (hypocretin-2) — the same precursor protein, but OX2R-biased and, unlike orexin A, rapidly degraded in blood rather than crossing into brain intact (Kastin & Akerstrom, J Pharmacol Exp Ther 1999).

• Dual orexin receptor antagonists — suvorexant (Belsomra), lemborexant (Dayvigo), and daridorexant (Quviviq) are FDA-approved oral insomnia drugs that do the opposite of orexin A: they block both receptors (BELSOMRA prescribing information, DailyMed).

• OX2R-selective agonists — oveporexton (TAK-861), danavorexton, and the discontinued TAK-994 are small molecules, not peptides, and are the route through which orexin-receptor stimulation is actually being developed as a medicine.

The practical consequence is that the pharmacology built on orexin A has moved toward orally available small molecules on both sides of the receptor. The peptide itself remains a laboratory reagent and a physiology probe.

Research on orexin A spans its foundational role in the biology of wakefulness, its connection to narcolepsy, and exploratory work on delivery routes such as intranasal administration for alertness and cognition. Much of the strongest evidence describes the endogenous peptide's physiology rather than outcomes from giving it as a therapy.

Because the applied evidence base is evolving, claims about orexin A as an intervention should be interpreted cautiously. High-level overviews are not a substitute for critical appraisal of primary data.

For deeper dives on this peptide, see:

• Orexin A benefits and areas of interest
• Orexin A side effects and safety context
• Orexin A dosing concepts (educational)
• Orexin A research and evidence overview

If losing orexin causes narcolepsy, why are the approved orexin drugs blockers? Because the two facts point in opposite directions and the blocking direction was easier to drug. Hypocretin-1 (orexin A) was undetectable in the cerebrospinal fluid of seven of nine people with narcolepsy (Nishino et al., Lancet 2000), and autopsy work found a global loss of hypocretins in narcoleptic brains (Peyron et al., Nat Med 2000). The mirror image of that deficiency is sedation — so antagonists became insomnia drugs. Three are FDA-approved: suvorexant (Belsomra), lemborexant (Dayvigo), and daridorexant (Quviviq) (BELSOMRA label, DailyMed).

Is anyone developing an orexin agonist? Yes, but not the peptide. Oveporexton (TAK-861) is an oral OX2R-selective small molecule. In a phase 2 trial of 112 adults with narcolepsy type 1, Maintenance of Wakefulness Test sleep latency rose 12.5 to 25.4 minutes across dose groups versus a 1.2-minute decline on placebo, with Epworth scores falling 8.9 to 13.8 points (Dauvilliers et al., N Engl J Med 2025). An earlier compound in the same class, TAK-994, was discontinued for dose-dependent liver toxicity (Arif et al., Ann Med Surg 2026). Nothing in that programme involves injecting or inhaling orexin A itself.

Has intranasal orexin A been given to people? Yes, in small physiology experiments rather than efficacy trials. In a double-blind crossover study, 10 healthy men received 500 nmol intranasal orexin A or placebo; resting muscle sympathetic nerve activity rose (5.8 versus 2.1 additional bursts per minute, p = 0.007) while blood pressure, heart rate, and baroreflex sensitivity did not change (Meusel et al., J Neurophysiol 2022). The widely cited cognitive result is in monkeys, not humans: nasal orexin-A improved performance in sleep-deprived macaques and outperformed the highest intravenous dose tested (Deadwyler et al., J Neurosci 2007).

What actually separates orexin A from orexin B? Receptor reach and survival in blood. Orexin-A signals through both OX1R and OX2R while orexin-B signals mainly through OX2R (Scammell & Winrow, Annu Rev Pharmacol Toxicol 2011). And orexin A crosses the blood-brain barrier from blood by simple diffusion, whereas orexin B is rapidly degraded in blood with no intact peptide detectable in brain after peripheral injection (Kastin & Akerstrom 1999). See orexin B for that side of the comparison.

Why is it called "orexin" if it is a wakefulness peptide? The name comes from appetite, not sleep. The 1998 Cell paper that identified both peptides reported that when given centrally to rats they stimulated food consumption, and that prepro-orexin messenger RNA increased on fasting (Sakurai et al. 1998). The wakefulness role was recognised afterwards, when narcolepsy was traced to this system.

Is there a registered clinical trial of orexin A as a treatment? No. A search of ClinicalTrials.gov returns orexin studies that either measure endogenous orexin levels or administer orexin receptor antagonists — none that give orexin A as an intervention. There is no approved orexin A product in any jurisdiction, no established dose, and no safety dataset beyond single-dose experiments in a handful of volunteers.